CARM (CARISMA Therapeutics) EPS (Basic): $0.20 (TTM As of Sep. 2025)


What is CARISMA Therapeutics EPS (Basic)?

CARISMA Therapeutics CARM +1.25% EPS (Basic) is $0.20 as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2025 was $1.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2025 was $0.20.

CARISMA Therapeutics's EPS (Diluted) for the three months ended in Sep. 2025 was $1.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $0.20.

CARISMA Therapeutics's EPS without NRI for the three months ended in Sep. 2025 was $1.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was 0.30.

During the past 3 years, the average EPS without NRI Growth Rate was -13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, CARISMA Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -13.00% per year. The lowest was -54.30% per year. And the median was -33.65% per year.

CARISMA Therapeutics  (OTCPK:CARM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CARISMA Therapeutics EPS (Basic) Related Terms

CARISMA Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics EPS (Basic) Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
-0.70 -1.01 -1.52 -2.59 -1.46

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.42 -0.22 -0.23 1.07

CARISMA Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CARISMA Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-60.477-0)/41.456
=-1.46

CARISMA Therapeutics's Basic EPS for the quarter that ended in Sep. 2025 is calculated as

Basic EPS (Q: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(44.717-0)/41.788
=1.07

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.20 mean?
CARISMA Therapeutics (CARM) has a EPS (Basic) of $0.20 as of Sep. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' EPS (Basic) too high?
CARISMA Therapeutics' current EPS (Basic) is $0.20.
How does CARISMA Therapeutics' EPS (Basic) compare to VRTX and REGN?
CARISMA Therapeutics' EPS (Basic) of $0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current EPS (Basic) is $0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current EPS (Basic) is $0.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current EPS (Basic) is $0.20 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.